Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Leqvio sales skyrocketed 83% to $223 million ... driven mainly by emerging growth markets. Novartis has a collaboration agreement with Roche RHHBY for Xolair. Novartis and Roche co-promote Xolair ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novartis forecasts further profit and sales ... cholesterol treatment Leqvio and multiple sclerosis medicine Kesimpta--offset a one-percentage-point hit from generic competition.

Novartis AG NVS, a Swiss pharma giant ... respectively. Strong growth in Leqvio, too, has likely fueled sales in the fourth quarter. The Zacks Consensus Estimate and our model estimate for ...